Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Mylan Inc. Stories

2013-04-03 16:24:16

PITTSBURGH, April 3, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Acyclovir Ointment USP, 5%. This product is the first generic version of Valeant International's Zovirax(® )Ointment, which is indicated in the management of initial genital herpes and in limited non-life-threatening mucocutaneous herpes...

2013-03-18 12:28:30

PITTSBURGH, March 18, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate). This product is the generic version of Sunovion's Xopenex(® )Inhalation Solution, which is indicated for the...

2013-03-13 16:25:54

PITTSBURGH, March 13, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with Shionogi Inc. and Andrx that will resolve patent litigation related to Metformin Hydrochloride Extended-release Tablets USP, 500 mg and 1000 mg. This product is the generic version of Shionogi's Fortamet(®), and is indicated as an adjunct to diet and exercise to lower blood glucose.(1) Under the terms of the...

2013-03-08 08:23:29

LONDON, March 8, 2013 /PRNewswire/ -- The U.S. Supreme Court last year upheld President Obama's Affordable Care Act (ACA). The ACA is the biggest overhaul of the healthcare industry in decades. While critics say that ACA will have a negative impact on the healthcare industry, supporters of the reform believe that the increase in the amount of insured individuals will ultimately benefit the industry. Apart from ACA, another major trend that is having an impact on drug makers...

2013-03-04 16:26:07

PITTSBURGH, March 4, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Annual Report on Form 10-K, containing audited consolidated financial statements for the year ended Dec. 31, 2012, as filed with the U.S. Securities and Exchange Commission on Feb. 28, 2013, is available through its Web site (www.mylan.com). In addition, the company's shareholders may receive a hard copy of the Annual Report, free of charge, upon request to Investor Relations at 724.514.1813....

2013-03-01 08:27:29

HONG KONG, March 1, 2013 /PRNewswire/ -- Pennystocksinsiders.com (PSI) has issued insider trading reports and equity research for the following companies: Vale SA (NYSE:VALE), Mylan (NASDAQ:MYL), eBay (NASDAQ:EBAY), Ford Motor (NYSE:F), Abbott Laboratories (NYSE:ABT), and Annaly Capital Management (NYSE:NLY). (Logo: http://photos.prnewswire.com/prnh/20130130/HK50859LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to your browser.) Report...

2013-02-28 08:30:00

NEW YORK, February 28, 2013 /PRNewswire/ -- Today, Investors Alliance announced new research reports highlighting Endo Health Solutions Inc (NASDAQ: ENDP), Actavis Inc (NYSE: ACT), Mylan Inc. (NASDAQ: MYL), Elan Corporation, plc (NYSE: ELN) and Amgen, Inc. (NASDAQ: AMGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Endo Health Solutions Inc Research Report Endo...

2013-02-27 16:28:09

Acquisition expected to be immediately accretive to adjusted diluted EPS upon closing PITTSBURGH, Feb. 27, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has signed a definitive agreement to acquire Agila Specialties Private Limited, a developer, manufacturer and marketer of high-quality generic injectable products, from Strides Arcolab Limited (BSE: 532531, NSE: STAR) for $1.6 billion in cash. The acquisition of Agila will create a global injectables...

2013-02-27 16:27:52

Announces 2013 adjusted diluted EPS guidance range of $2.75 - $2.95 PITTSBURGH, Feb. 27, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three months and year ended December 31, 2012. Financial Highlights Adjusted diluted EPS of $0.65 for the three months ended December 31, 2012 compared to $0.53 for the same prior year period, an increase of 23% Total revenues of $1.72 billion for the three months ended December 31, 2012 compared to...

2013-02-25 08:30:29

PITTSBURGH, Feb. 25, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has begun shipping Fenofibrate Capsules USP, 43 mg and 130 mg. This product is the generic version of Lupin Atlantis Holdings, S.A.'s Antara(®) Capsules, which are indicated as an adjunct to diet to reduce elevated LDL-C, Total-C, triglycerides, and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia and to reduce...